MaxCyte Inc.

MXCT | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.23

+$0.01 (+0.82%)

Sep 22, 2026, 2:45 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.82%

(1D)

Rating

Updated: Sep 19, 2026

31.2

Fundamentals Weak

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $131.22M

1D Range

1.20 1.23

52W Range

0.64 1.87

Valuation (TTM)

PE -3.70

PB 0.82

EV/EBITDA -1.30

Valuation (NTM)

Forward PE N/A

Forward PEG 0.62

Price Target $6

Cash Flow

FCF Yield -18.2%

SBC Adj. FCF Yield -19.6%

SBC Impact -7.8%

Margins

Gross Margin 79.4%

Operating Margin -111.6%

FCF Margin -76.6%

Growth (CAGR)

Revenue 3Y | 5Y -8.6% | 1.5%

Dil EPS 3Y | 5Y 1.4% | -14.1%

FCF 3Y | 5Y 2.7% | -4.3%

Returns

ROA -19.3%

ROE -21.0%

ROIC -19.7%

Financial Health

Net Cash

$105.69M

Current Ratio 12.26

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static elec...

Sector Healthcare

Industry Biotechnology

Employees 91

IPO Date Jul 28, 2021

Website www.maxcyte.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+387.80%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞